PatternsRadar
Sign in

EMCUREEmcure Pharmaceuticals Limited

NSEBand 10%
2,337.80INR-6.90 (-0.29%)Close · 20 Nov 2026
3 Nov 2026Last results
HealthcareSector
Pharmaceuticals & BiotechnologyIndustry
₹44,351 CrMarket cap
40.6P/E (TTM)
52.3%Delivery

Filings & corporate actions

10 results filed
CSV
Next results · Q3 FY27
Expected 3 Feb 2027 – 21 Feb 2027
Estimate: filed 34–52 days after quarter end, last 8 times
Dividend
₹3.60 per share · last 4 Sept 2026
2026
  • 3 NovresultsResults · Q2 FY27 · consolidated and standalone+9.3%NSE
  • 19 OctshareholdingShareholding · 30 Sept 2026-3.0%NSE
  • 4 SeptdividendDividend · ₹3.60 per share+3.9%
  • 6 AugresultsResults · Q1 FY27 · consolidated and standalone-1.1%NSE
  • 21 JulshareholdingShareholding · 30 Jun 2026+3.4%NSE
  • 5 MayresultsResults · Q4 FY26 · consolidated and standalone-1.8%NSE
  • 17 AprshareholdingShareholding · 31 Mar 2026+2.0%NSE
  • 4 FebresultsResults · Q3 FY26 · consolidated and standalone+1.9%NSE
  • 20 JanshareholdingShareholding · 31 Dec 2025-0.9%NSE

Reaction to results · all yearsrose on day 0 in 5 of 10 CSV

QuarterFiledDay 0+5D+20DRel vol
Q2 FY273 Nov 2026+9.3%+12.9%—8.1×
Q1 FY276 Aug 2026-1.1%+2.6%-5.3%1.8×
Q4 FY265 May 2026-1.8%-2.0%+3.2%1.6×
Q3 FY264 Feb 2026+1.9%-0.5%-3.5%1.8×
Q2 FY2611 Nov 2025-2.4%0.0%+2.9%1.2×
Q1 FY267 Aug 2025-1.5%+2.3%-4.8%2.3×
Q4 FY2522 May 2025+10.0%+13.9%+12.4%3.1×
Q3 FY256 Feb 2025+2.8%-14.8%-22.3%2.9×
Q2 FY258 Nov 2024-3.2%-9.3%-5.0%7.5×
Q1 FY2513 Aug 2024+0.5%+9.9%+16.6%1.5×
Average+1.5%+1.5%-0.6%

Close-to-close from the session before the filing could trade. Day 0 is the first session after it.

Growth · Q2 FY27

Revenue YoY+24.3%
Profit YoY+33.7%
Interest cost YoY+16.4%
Revenue QoQ+9.3%
Profit QoQ+10.7%
CAGR2Y3Y4Y5Y6Y7Y
Revenue——————
Profit——————

Key data

Open2,357.90
Day range2,331.00 – 2,389.00
52-week range1,312.30 – 2,429.90
From 52w high-3.8%
RSI (14)72.9
ATR (14)79.71
Volume79.0K
Avg volume (20D)3.04L
Rel volume0.26×
Volatility (1Y)32.9%
Turnover₹18.6Cr
Traded value (NSE)₹18.6Cr
VWAP2,353.22
SMA 50 / 2001,999.59 / 1,777.34
Price band10%

Delivery percentage

Latest · 20 Nov 202652.3%
20-day avg52.5%
1-year avg50.6%
Percentile (own history)45th
Range12.6–93.4%
Sessions588

Over the last 20 sessions EMCURE settled 52.5% of its traded quantity, which is above average for an NSE equity. That is in line with its own one-year average of 50.6%. The latest session ranks higher than 45% of the 588 sessions on record for it.

What delivery percentage measuresScan the whole market on delivery

Dividends, deals & holders

Dividend yield0.15%
Dividend, trailing 12M₹3.60
Paid every year for2 yr
Shareholders1.29L · +3.5% QoQ
Net bulk deals, 30D0.00%
Block deals, 30D₹0
Last bulk buy164 days ago

Performance returns

1D1W1M3M6M1Y
Price-0.29%-1.01%+31.15%+24.26%+33.47%+70.42%

Valuation

Market cap₹44,351 Cr
Market cap (NSE)₹44,351 Cr
Free-float cap₹9,837 Cr
P/E (TTM)40.6
P/E (NSE)40.7
EPS (TTM)57.64
P/B8.3
Net margin (TTM)10.7%
Other income / PBT0.7%
ROE21.7%
Debt / equity0.27
Shares outstanding18.97Cr
Listed10 Jul 2024

Ownership

Promoter77.82%
Promoter Δ QoQ-0.01 pp
Public22.18%
FII4.94%
DII8.49%
Pledged0.04%

Quarterly results · consolidated

Q3 FY26Q4 FY26Q1 FY27Q2 FY27
Revenue (₹ Cr)2,363.52,469.72,580.42,820.5
YoY chg+20.4%+16.7%+22.8%+24.3%
Net profit (₹ Cr)231.4243.7292.5325.1
YoY chg+48.2%+23.6%+36.2%+29.3%
Net margin9.8%9.9%11.3%11.5%
EPS12.1612.8415.5017.14

Shareholding over time

By quarter

30 Sept 2026 · promoter 77.82% · public 22.18%
8 Jul 2024: promoter 78.08%30 Sept 2024: promoter 78.08%31 Dec 2024: promoter 77.94%31 Mar 2025: promoter 77.92%30 Jun 2025: promoter 77.91%30 Sept 2025: promoter 77.88%31 Dec 2025: promoter 77.87%31 Mar 2026: promoter 77.87%30 Jun 2026: promoter 77.83%30 Sept 2026: promoter 77.82%
2024-072026-09
  • Promoter
  • Public and others
Promoter
77.82%
Public
22.18%
Promoter change
-0.01 pp
Filed
19 Oct 2026
FII
4.94%
DII
8.49%
Promoter pledged
0.04%

Who the public is

Mutual funds
7.05%

+0.18 pp QoQ

Insurance
1.19%

-0.14 pp QoQ

FPI
4.94%

+0.07 pp QoQ

Retail ≤ ₹2L
2.93%

-0.07 pp QoQ

HNI > ₹2L
3.41%

-0.04 pp QoQ

NRI
0.75%

0.00 pp QoQ

Bodies corporate
1.21%

+0.04 pp QoQ

Shareholders
1,29,328

+3.5% QoQ

Major holders

As of 30 Sept 2026
HolderTypeHolding
Satish R MehtaPromoter · Individual39.74%
Everest Trust (Shares held by Sanjay Rajanikant Mehta with Sonali Sanjay Mehta, as trustees)Promoter · Other7.65%
Unity Trust (Shares held by Sunil Rajanikant Mehta with Kamini Sunil Mehta, as trustees)Promoter · Other7.65%
Samit Satish MehtaPromoter · Individual7.14%
Bhavana Satish MehtaPromoter · Individual4.70%
Namita Vikas ThaparPromoter · Individual2.67%
Kotak Midcap FundMutual fund2.31%
Pushpa Rajnikant MehtaPromoter · Individual2.05%
Sanjay Rajanikant MehtaPromoter · Individual1.95%
Sunil Rajanikant MehtaPromoter · Individual1.50%

Every promoter-group member, and each public holder above 1%, as filed.

Promoter and public shares of total equity, from the pattern filed each quarter. Institutional, pledge and public-breakdown figures come from the filing's XBRL, which most filings before Sep-2021 lack, so they are absent there rather than zero. Changes are against the previous filing.

Dividends

since 14 Aug 2025 CSV
Financial yearPaymentsDeclaredAdjusted
FY2026-271₹3.60₹3.60
FY2025-261₹3.00₹3.00
Ex-dateRecord dateDeclaredAdjusted
4 Sept 2026—₹3.60₹3.60
14 Aug 2025—₹3.00₹3.00

Rupees per share by ex-date, from NSE’s corporate actions; the record date is who was paid. Declared is the figure in the filing; adjusted restates it for splits and bonuses since, on the same basis as the price chart. Financial years run April to March.

52-week highs & lows

Loading…

Each session the stock traded past its previous 52-week high or low, from NSE's daily report; the previous figure is the record it broke. Prices as published, not split-adjusted.

Price-band hits

Loading…

Sessions the stock closed at the limit of its daily price band, from NSE's end-of-day list. A stock pinned at the band could not trade past it that day.

Book closures & record dates

Loading…

NSE's corporate-action calendar: who held the stock on the record date, or through the book-closure window, was entitled to the dividend, bonus, split or rights named.

Bulk & block deals · 25 Jun 2026

CSV
12 of 17 deals
By year
DateDealClientQuantityPriceValue
25 Jun 2026Sell · block, also bulkBC INVESTMENTS IV LIMITED9.70L1,817.00₹176.2Cr
25 Jun 2026Sell · block, also bulkBC INVESTMENTS IV LIMITED9.70L1,817.00₹176.2Cr
25 Jun 2026Buy · blockHDFC STANDARD LIFE INSURANCE COMPANY LTD5.57L1,817.00₹101.2Cr
25 Jun 2026Buy · blockADITYA BIRLA SUN LIFE MUTUAL FUND2.61L1,817.00₹47.5Cr
25 Jun 2026Buy · blockHDFC STANDARD LIFE INSURNACE1.58L1,817.00₹28.7Cr
25 Jun 2026Buy · blockALPHA ALTERNATIVES EQUITY ABSOLUTE RETURN FUND1.38L1,817.00₹25.0Cr
25 Jun 2026Buy · blockBNP PARIBAS FINANCIAL MARKETS1.38L1,817.00₹25.0Cr
25 Jun 2026Buy · blockAXIS MUTUAL FUND1.38L1,817.00₹25.0Cr
25 Jun 2026Buy · blockAXIS MUTUAL FUND1.38L1,817.00₹25.0Cr
25 Jun 2026Buy · blockGOLDMAN SACHS INVESTMENTS MAURITIUS I LIMITED1.38L1,817.00₹25.0Cr
25 Jun 2026Buy · blockHSBC MUTUAL FUND1.38L1,817.00₹25.0Cr
25 Jun 2026Buy · blockMORGAN STANLEY ASIA SINGAPORE PTE1.38L1,817.00₹25.0Cr

A bulk deal is a client trading over 0.5% of the company’s shares in a day; a block deal is one large trade in the separate block window. Quantities and prices are as NSE published them, not split-adjusted.

Every stock on this session →

Short selling, lending & margin

Loading…

Shares sold short on the day, as brokers reported them to NSE at the close. As reported, not split-adjusted.

Exchange surveillance

20 Nov 2026
  • Price move > 25% in 1 month · since 13 Nov 2026 — One of the criteria NSE’s surveillance watches: price move > 25% in 1 month.

Price band: 10% · not in the F&O ban.

From NSE’s daily surveillance, price-band and position-limit files. A stock enters the F&O ban when open interest passes 95% of its market-wide position limit and leaves it below 80%; until then no new positions can be opened. CSV: measures · band changes.

Every stock on this session →

Financials · quarterly statement

₹ crore, as filed
By year
 Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27Q2 FY27
Revenue from operations1,815.12,002.01,962.62,116.22,100.52,269.82,363.52,469.72,580.42,820.5
Other income23.435.73.94.53.73.11.94.02.13.3
Total income1,838.62,037.61,966.52,120.72,104.22,272.92,365.32,473.72,582.52,823.7
Total expenses1,631.21,764.21,736.61,849.71,810.01,931.52,013.42,142.82,189.02,377.9
└ Finance costs58.846.231.839.026.832.538.046.431.535.6
└ Depreciation93.696.996.896.899.5104.6104.7106.3109.5109.7
Profit before tax207.4273.4229.9260.6290.8341.4313.8341.2393.5445.9
Tax expense54.871.973.863.476.090.082.497.4101.0120.8
Net profit152.6201.5156.1197.2214.8251.4231.4243.7292.5325.1
EPS7.9510.338.129.9710.9212.8512.1612.8415.5017.16
Net margin8.41%10.07%7.95%9.32%10.23%11.07%9.79%9.87%11.33%11.53%
PBT margin11.43%13.66%11.71%12.31%13.84%15.04%13.28%13.81%15.25%15.81%
Tax rate26.43%26.28%32.11%24.32%26.13%26.37%26.27%28.56%25.67%27.09%

A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. The balance sheet and cash flow arrive only with the half-year and annual filings, and are in their own section below. Latest filed 3 Nov 2026.

Balance sheet & cash flow · half-yearly

₹ crore, as filed
By year

Balance sheet

 H1 FY25FY25H1 FY26FY26H1 FY27
Total assets8,124.58,232.79,392.59,612.510,163.8
Current assets4,547.64,649.95,700.45,709.06,142.9
└ Cash & equivalents162.1155.5472.3136.7136.6
└ Other bank balances25.09.817.310.910.8
└ Current investments45.376.022.50.00.0
└ Trade receivables2,029.52,002.22,299.92,562.72,731.4
└ Inventories1,751.61,931.82,304.62,397.92,504.6
Total equity4,303.34,641.64,884.04,976.75,344.0
└ Attributable to owners4,118.44,446.24,742.64,950.05,344.0
└ Non-controlling interest185.0195.4141.526.60.0
└ Share capital189.1189.5189.6189.6189.7
Borrowings941.8731.71,344.11,204.11,467.3
└ Current657.8541.81,024.7951.9930.1
└ Non-current284.0189.9319.4252.2537.2
Trade payables1,506.91,479.61,725.41,807.82,026.4
Current liabilities2,832.12,668.33,686.03,912.23,838.9
Total liabilities3,821.23,591.24,508.54,635.84,819.7
Net debt709.4490.4832.01,056.61,320.0
Debt / equity0.220.160.280.240.27
Current ratio1.611.741.551.461.60

Cash flow, year to date

 H1 FY25FY25H1 FY26FY26H1 FY27
Operating cash flow360.2851.7256.2943.5682.2
└ Capex(192.7)(406.9)(189.0)(547.7)(371.8)
Free cash flow167.5444.867.2395.9310.5
Investing cash flow135.1(94.0)(410.8)(1,193.1)(566.9)
Financing cash flow(383.8)(814.0)629.1343.4(153.4)
└ Dividends paid0.00.0(56.9)(56.9)(68.3)
└ Buybacks0.00.00.00.00.0
Net change in cash110.6(58.3)484.693.9(36.5)

From the half-year and annual results filings: the balance sheet from September 2022, the cash flow from September 2020. Those are when NSE’s XBRL began to carry each statement; earlier filings have it only in the attached PDF. Cash flow columns are year to date, so an H1 column covers April to September and an FY column the full year. Outflows are in parentheses. Net debt is borrowings less cash, bank balances and current investments; for banks, NBFCs and insurers it, debt to equity and the current ratio are left blank because their statements are not built that way.

Announcements & board meetings

Loading…

As the company filed them with NSE, newest first. Board meetings are dated by the meeting, which is usually a week or more after the intimation.

Every stock on this session →

EMCURE at a glance

  • EMCURE closed at ₹2,337.8 on 20 Nov 2026, -0.29% on the day, +70.4% over one year, 3.8% below its 52-week high of ₹2,429.9.
  • Delivery was 52.3% of traded quantity on 20 Nov 2026, the 45th percentile of its own 588 sessions with a reading (20-session average 52.5%, 1-year average 50.6%).
  • Market capitalisation is ₹44,351 crore at a trailing P/E of 40.6 (trailing EPS ₹57.64).
  • Q2 FY27 results (consolidated, filed 3 Nov 2026): revenue ₹2,820 crore (+24.3% year on year), net profit ₹325 crore (+29.3%); the price moved +9.3% on the first session after.
  • Promoters held 77.82% at 30 Sept 2026, down 0.01 percentage points on the previous filing, with 0.04% of promoter shares pledged.
  • Q3 FY27 results are expected between 3 Feb 2027 and 21 Feb 2027, going by past filing dates — an estimate, not an announcement.

About

Macro sectorHealthcare
Basic industryPharmaceuticals
ISININE168P01015
SeriesEQ
Listed10 Jul 2024
IPO price1,008.00 · band Rs.960 to Rs.1008
IPO listing10 Jul 2024
NSE market cap · 17 Nov 2026₹44,381 Cr
Free-float market cap (NSE)₹9,763 Cr
Shares outstanding (NSE)18.97Cr
History from10 Jul 2024
Sessions588
Turnover rank#371

Sector history

  1. to 16 Aug 2026Index industry · Healthcare
  2. from 16 Aug 2026Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals

NSE’s own classification, by the snapshot it changed on.

Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 20 Nov 2026.